ONCE pain, homorrhage, and infection were brought under reasonable control, and as our knowledge of normal and abnormal function became more secure, the magnitude of an operation could be extended nearly indefinitely. Many operations came to be looked upon as subtotal eviscerations. Surgeons often believed that the end results of the surgery for many malignant tumours would be greatly improved merely by extending the limits of resection. Unfortunately, we have come to know that once malignant disease has spread beyond the organ of its origin, it is all too often extraordinarily difficult to eradicate. While the end results of surgery for cancer of the major viscera have without doubt improved during the last twenty-five years, they have not improved sufficiently to still the search for better methods of therapy.
There are too many generalizations concerning cancer. All too frequently it is spoken of as if it were a single disease. The intimation is that the life history of cancer in a major viscus is always the same. Actually we know that it is often not the same disease even in the same organ. In some instances the lesion spreads so slowly that one wonders whether it is truly a malignant lesion, and in other instances a cancer which histologically looks quite similar spreads as rapidly as a prairie fire.
Thoughtful interniists, surgeons, and radiologists realize more than ever before the present inadequacies of therapy. The majority of these individuals admit freely that once malignant disease has spread beyond the organ of its origin it is nearly impossible to eradicate. It must be freely admitted that cancer confronts the surgeon with many of his most difficult and exasperating problems. Three and five years survivals for such common carcinomas as those of the stomach and the breast taken as a whole do not exceed 10 and 30 per cent. respectivelv, where there has been no selection of cases.
An obvious way to improve these data is to establish the diagnosis earlier in an attempt to forestall the spread of the disease beyond the range of the scalpel. Extensive education of physicians and laity has been undertaken. Diagnostic methods are being improved. Pathologic examinations of cells exfoliated from the surfaces of the lung and uterus offer promise for the diagnosis of early not easily accessible cancers, and may be widely applicable to cancers of hollow organs, although as yet they have not been proven to be as useful as we had initially hoped they would be. Cancer cells can be found in the blood stream of patients with cancer of certain of the major viscera, and this finding is so frequent that one woniders why any patient can ever survive once the disease has been initiated.
Due to the insidious nature of the disease, its failure to produce svmptoms in its incipienlt stages, and its often extremelv rapid spread to distant locationls, it is evident that under the best practical conditions of diagniosis and technical liberty, surgerv, as we know it now, can anticipate a level of efficiency w%ell below a desirable standard. We shall have to find more potent adjuncts of therapy before cancer is better controlled. We must have a keener insight into the character of cancerous tissues, their failure to conform wvith normal cellular organization, and their energetic metabolic needs.
Extirpation of tissue alone, or in conjunction with radiotherapy is perhaps, at present, the best available regimen. Their possibilities are perhaps not yet exhausted, but we must begin to look for other means of therapy as the limitations of these older methods have been reached. The surgeoni rightly in my own country has been aligning himself with other investigators into the nature of neoplastic tissue. There can be no phase of this subject for which the surgeon does not have a pertinent concern. Surgeons must know what is being done in research in malignant disease and must vigorously assist in the clinical application of the research findings.
Antibiotic and chenmotherapeutic agents have assisted greatly in the surgical care of suppurative infectionls. The surgical treatnment of certain patients wvith tuberculosis by lobectomy and pneumonectomy, discarded years ago as being unsurmountably perilous, has been revised, not because of streptomycin, but because of the w ider knowledge of the physiologic basis of thoracic surgery and the increased knowledge of the disease itself. Due to the poorly understood, but unequivocal inhibitory influence of the spleen on the cellular elements of the blood, splenectomv is a dramatic therapy for certain anrmias, leukopenias, and thrombocytopenias, and the syndromne of depression of all three elements, hypersplenism, or primary splenic panhematocvtopenia.
In ni-anv of our university institutionis and in certain of our distinguished cancer institutes, and no doubt in similar institutions in your own country, individuals are concernied with basic research in order that new knowledge may assist in unravelling the problems associated with the causes and nature of malignant disease. In many of these institutions, and especially in many of our great hospitals, other individuals, primarily clinicianis who have had varying amlounits of traininig in good clinical research, are playing significant roles in the chemotherapy of late malignant disease with the hope that through the use of a variety of chemotherapeutic agents which are being made available, we may find better methods for the complete therapy of malignant tumours.
I am suire that there exists areas in which our concepts of cancer are not changing as rapidlv as the facts warrant. There are many areas where the application of research findings has lagged. The clinician must play his full part in this work. Who else knows the life history of clinical cancer so well?
A number of young surgeons are participating actively in the use of chemotherapeutic agents which are being administered to patients at the time of operation for cancer of-the lung, cancer of the stomach, cancer of the colon, cancer of the prostate, and cancer of the ovarv. This is being done with the hope that certaini of these agents will improve the end results which are now being obtained by surgery, or by surgery anid X-ray alone. Already data are available to show that in tlle case of mammary cancer this can be done.
I have had it said to me that the adjuvant chenmotherapy programme, as well as certain aspects of the chemotherapy programmne in general, is an irrational approach to the major problems of malignant disease. Individuals who support this point of view believe that we must first have a fuller understanding of the precise basic nature of cancer. The historv of medical progress does not support their point of view. I am afraid that these individuals may not be fully conversant with previous contributions to medicine wvhich over many, many years have come to significantly effect a variety of disorders which have plagued mankind.
Lister knew verv little about bacteriology when he developed the aseptic theory for the control of infection at operation. While Banting and Best made insulin available in 1921, scientists have been working in the intervening years in order that we might have a clearer concept of the manner in which insulin acts. The sulphonamides became available in the mid-thirties, and ten years later we were not sure of the biological processes by which these agents acted. Penicillin became available in 1943, and within the next ten years an increasing number of antibiotics became available for clinical therapy, at a time when it 9 n)
was not clear what biological reactions were concernied in the control of the organisms causinig infection.
I milust agree with Paul Weiss when he said, "Real science is earthy; just onle of nmany branches of the human enterprise; one to be cultivated, but nlot a cult. Science mulst miiake more men its devotees, 1)ut nonie its priests."
Finialiv it is said bv manll internists in mV countrv that surgeons ought not to be playin(yg a. significalnt role in the chemotherapy of nmalignant ttnl)ours.
I have on mlore than one occasion counselled mlly mnedical colleagues to read Harvey Cushing's address on "Realignnments of the Greater Medicinie ancd Surgerv," which address was given at the Third Interniational Congress On Medicine and Surgerv in London in June, 1913. It was then that he said, "The voung surgeonl of the future will be an interniist first and a surgeon later."
The surgeonis of this coUlltrv and of mine really control at one time or another the mnajority of patients wvith solid maligniant tumours. Many of these individuals are experieniced investigators and a worthwhile nuimiber of them have made significant contributions to our basic knowledge of a variety of disordered states. This is a field in which basic scientists, internists, and surgeons must work together, each functionling in that particular area in wrhich he has a major interest. Are we doing evervthing possible to advance research findings from the basic science laboratory to the clinic? Unless we all rcalize our responsibilities, we mav well be in the position of retarding progress. We must be awake to the miianv exciting findings being uncovered in votur coutntrv and mine which have a close relationship to the canicer probleml.
In an article on the "Chenmotherapy of Solid T umours," bv Dr. Robert Glenn Ravdin and XVillianm L. Elkinis the following statement is found, "The situation at present in the chemnotherapy of solid tumours is perhaps comparable to that in suirgery at the turn of the century or in radiotherapy some three decades ago: ainumber of different techniques compete for attention, nost of which are uinstalndardized, inadequately evaluated, heavilyv influenced by vogue and attend(le(d by considerable morbidity, not to say hazard. At the same time, a fesv outstanidinglv brilliant accomplishments indicate that labours along these lines are not fruitless. In order to lay a groundwork for a more specific discussionl, some generalities can be first dealt with."
It cannot be denied that the chemotherapy of malignant tumours is a specialized cndeavouir. Many of the agents are toxic and require considerable experience in their administration. They do not act uniformly even on similar tumours. There are available, however, a group of agents of varying chemical design which do affect a variety of malignant tumours. These and related agents deserve careful scrutinv through clinical trial. Such studies must be carried out in fairly large-scaled programmes. We are even at this time not yet completely sure as to the optimal dosage of certain of these agents, the rate of their administrationi, and the method of their administration.
Some of these drugs are not toxic when given in minimal dosage, but it is equially true that they are not cancerocidal unless they are administered to the poinlt of toxicity. As Ravdin anld Elkins have pointed out, "The differential b)ct\ een the susceptibilitv of tumours and that of noriiial tissuLes is relati\-ely smiiall (for the agentts \e now lhave); a tumi)our will prol)ably not be affected by a dose of drug which is not injurious to the miiore senlsitivC of the normiial tissues: Tumlour cells share the common biochemical mechanisnms of normal cells; extensive investigation at the biochemical level has turnied up only quantitative differences, and manyv of these are not pronounced. Exploitation of these differences has not reached a stage that may in any sense be described as refined.
Indeed, the mlost effective drugs seemi in cssence to affect cells in rough proportioin to their growth rate, anid thereforc, in sonmewhat varying degree, to be particuilarly nloxious to hematopoietic tissue and the gastrointestinal mucosa. However, the concept of reaching a desired goal by subjecting a patient to an injurious procedure is not foreign to the surgeoni. It should be noted parenthetically that although chemlotherapeutic agenits mayn inlterfere with host resistance in certain experimental situationis in animllals b)earlng tranisplanted ttumilours, there is no convincing evi'dence that these findinigs miiay be extrapolated to spontaneous tumours in the humaii. This is by nio mleans a closed question."
The idea that the progress of malignant diseases might be controlled in part or in whole bv chenmotherapy is surely not a new one. Anidrogenls and estrogenis have been demonstrated to retard the spread of certain malignant tumours of the breast and to cause regression in areas of metastasis once this has taken place. Other agents have l)een fotund to be useful in certain of the leukemias. It is an unfortunate circumlstacLaie that while mlany of these agents have been found to be extraordinarill useful in certain tumours of a mlalignanit nature found in experimenital aninmals that they have not been found to be useful when used in similar tumours in nman. The agents that we are using are classified as alkylating agents, antimetabolites, antibiotics, and a miscellaneous group of agents such as the hormones. The alkvlating agents, which are frequenitly called the mlustards, have been used in a wide variety of malignant tumours. The exact mechanism by which thev function is not as yet definitelv determined. These nitrogen mlustards, as they are very comnmonly called, act by mlaking the nucleic acids as their targets. Thio-TEPA, TEM, Myleran, anid Cytoxani or Endoxani belong to this general group. Some of these can be given orally which is at tinmes a decided advantage. Cytoxan rarely produces thrombocytopenia even in dosage levels which cause serious reduction in the lymphocytes. This provides a safety feature which we believe permits greater dosage than can be obtained with other alkylating agents. In our hands they have been most effective against the lymphomals, reticuluml cell sarcoma, ovarian anid nmanimarv carcinoma. While we have had some dramatic results with the use of certain of these agents, the dramatic improvement shown following therapy has been all too short. Perhaps readjustnments of the methods of dosage of administration of the drug nlight chanige this, but wve mlust look for more potent agents in this series.
The anitimetabolites constitute a group of diverse character which have the common characteristic "of accurately counterfeiting somiie normiial cellular conistituent."
In the area of antibiotic therapy for tumours the miost wivdely used agent has been actinomvcin D. It is a very effective agent for the cmbryonal carcinomas of the kidniey, the Wilms' tumour. It is also effective in certain tumours of the testis and in rhabdomyosarcomas and certain other undifferentiated sarconlas, especially those in children. We must attempt by every conceivable method to improve the activity of these agents againist the malignant tumours, and at the same time to reduce the toxicity, a task that nlow seemiis nearly hopeless. A large group of chemists in and out of goveriinlenit, and in and out of our chemical inidustries and our universities, are attempting to develop such additional agents for clinical trial following careful pharmacological study and screening of the agents in experimental systems. Certain individuals are suggesting combined therapy, and in the choriocarcinomas of the testis, methotrexate, chlorambucil, and actinomycin D used together have certainly proved to be superior to either one of these agents used alone. Sonme investigators are rigorously attempting to find less toxic agents which will potentiate the more effective toxic agents.
There is increasing evidence that radiation and chemotherapy will provide end resuits which are better than those when either therapy is used alone. I'his area is now being very carefully investigated.
Warren Cole suggested that greater salvage might be achieved by the concurrent adminiistration of effective chemotherapeutic agents at the time of and immediately subsequent to major surgical procedures. There is now evidence available to show that in carcinoma of the breast this is true, and it is highly probable that as more effective agents become available for other tumours, this attack nmav be broadened.
I am sure that this audience is familiar with the method developed in Dr. Creech's department at Tulane University in New Orleans and by other surgical groups in which high concentrations of an effective agent are introduced into an isolated circulation of a limited area. Thus, high concentrations of drugs can be obtained without producing general toxicity. Whether this method will prove of permanent usefulness remains vet to be determined but certain areas of the body can be perfused in what is essenitially a closed vascular system. I would hope that certain of the younger rnembers of this audience will become sufficiently interested in this important area of effort to spend a portion of their timne carefully studying the effect of a variety of agents now available and those which will soon be available in careful clinical investigation. Beware of pitfalls in this field! Subjective improvement is not a very reliable criterion. There are manv pitfalls in this area which the cliical investigator must come to know. Decrease in the volume of a measurable tumour mass is the most important criterion of effect. It is anl unfortunate circumstance that so often one cannot get bona fide measurenments. In some instances biochenmical properties of the tumour prove to provide valuable criteria of effectiveness, but the most important criterion is the extension of a useful life.
The organized Co-operative Clinical Studies now being carried on in my country have yielded solid quanititative data in a nmuch shorter time thacn any single institution could possibly have achieved. It has stimulated the interest and co-operation of manv internists and surgeons in the care and chemotherapy of advanced malignant disease. It has gained the confidence and active collaboration of the pharmaceutical industry. The programme has assisted in the training of hundreds of scientists and clinicians, not only in cancer research but in closely related fields. It has organized a national standard reporting system of end results in malignant disease, and such reports are now being made on more than 50,000 new cancer cases a year. It has developed biometric units in a number of our nmedical schools and other research institutions to provide statistical consultation not only for cancer chemotherapy, but for other research. It has made available the first truly unselected, complete data on a national basis of operative complications and mortality fronm gastric, pulmonary, and colorectal resections, and it has set the pattern for other research areas where extensive interinstitutional efforts are needed.
The builk of the chemicals examined during the past two years have come from the antibiotics programmes of industry and consist of crude beers. No rational approach is possible in the selection of anti-cancer antibiotics. Great skill anid experience, however, will account for the greater success of some laboratories. This programme of necessity must be largely empirical.
The rapid progress in the study of hormone analogues could not have been achieved by individual or unco-ordinated effort.
A similar study of the vast number of plant natural products is being undertaken.
The three tumour mouse screen is being subjected to careful analysis. This method, as well as all other screening methods, can be evaluated only when a sufficient number of candidate compounds show true effectiveness against tumours in man.
The vast majority of scientists interested in cancer chemotherapy are prepared to drop any method of screening presently employed when a more specific method is discovered. Until then it is essential to continue along the lines presently followed.
Preclinical pharmacology must be expanded to meet the needs of the clinician. It is understandable that pharmacologists are not anxious to undertake huge programmes of preclinical pharmacology without assurance that the compound is of real interest to clinicians. It is also clear that the clinician can evaluate the anti-cancer properties of a compound more quickly and accurately if he has precise information concerning time-dose relationships, excretion, metabolism, and distribution in the tumour and in the body.
The co-operative clinical studies carried out with the aid of the Center through its clinical panel have been responsible for achievements which could not have been brought about by any other organizational pattern or sponsorship to my knowledge. The large number of institutions and doctors who have voluntarily agreed to study the response to anti-cancer agents are organised to work together in small groups on the basis of protocols representative of specific experimental 13 designs adopted as representative of the best methods of evaluation of chemotherapeutic agents. Extensive modifications may arise from the critical evaluations presently under way. The greatest importance of the clinical co-operative trials lies in the fact that a large-scale attempt has been effectively carried out for actual clinical investigation based upon predetermined criteria. Data emanating from such studies permit analysis which otherwise could not be possible. The goals of individual studies in this co-operative plan were selected as much to achieve familiarity with this kind of clinical investigation as for the purpose of clinical investigation itself. It must be remembered that this kind of work is not as exciting as research of an individual scientist. It calls for obedience to rules, democratically achieved and agreed to. A by-product of such clinical interest is the great improvement in the care of patients with advanced cancer, and the conveyance of hope to the patient with such a serious problem because of the increased tempo of research activity concerning his or her problem. An important by-product, too, is the collection of information concerning the life history and biologic behaviour of the various forms of cancer. These by-products alone are worth the effort of the entire clinical programme so far.
Time does not permit me to describe the many exciting areas of research that are being prosecuted. In 1956, at the Third National Cancer Conference, Wendell Stanley suggested that for research purposes at least we might assume that all human cancer was viral in origin. The evidence is becoming stronger that Wendell Stanley may well be correct, and if he is, the justification of chemotherapy will indeed be on a firmer basis.
While the gains have been substantial, we have not yet achieved the goal wvhich we have set before us to achieve. I need not tell this audience that this large field, which takes such a heavy toll each year in your country, and in mine, and in many other countries in the world, will be solved. When it is we will understand that understanding science is a way of thinking and that science's task is to serve man.
